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A B S T R A C T
Our new compound, 5′-Br [(E)-1-(5′-bromo-2′-oxoindolin-3′-ylidene)-6-ethyl-2,3,6,9-tetrahydro-2,9-
dioxo-1H-pyrrolo[3,2-f]quinoline-8-carboxylic acid], had shown strong, selective antiproliferative activity
against different cancer cell lines. Here, we aim to comprehensively characterize the mechanisms asso-
ciated with its cytotoxicity in the human promyelocytic leukemia HL-60 cells. We focused at studying
the involvement of apoptotic pathway and cell cycle effects. 5′-Br signiﬁcantly inhibited proliferation by
inducing caspase-dependent apoptosis. Involvement of caspase independent mechanism is also possi-
ble due to observed inability of z-VAD-FMK to rescue apoptotic cells. 5′-Br was found to trigger intrinsic
apoptotic pathway as indicated by depolarization of the mitochondrial inner membrane, decreased level
of cellular ATP, modulated expression and phosphorylation of Bcl-2 leading to loss of its association with
Bax, and increased release of cytochrome c. 5′-Br treated cells were found arrested at G0/G1 phase with
modulation in protein levels of cyclins, dependent kinases and their inhibitors. Expression and enzy-
matic activity of CDK2 and CDK4 was found inhibited. Retinoblastoma protein (Rb) phosphorylation was
also inhibited whereas p21 protein levels were increased. These results suggest that the antiproliferative
mechanisms of action of 5′-Br could involve apoptotic pathways, dysregulation of mitochondrial func-
tions and disruption of cell cycle checkpoint.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Acutemyeloid leukemia (AML) is hematopoietic malignancy char-
acterized by uncontrolled proliferation and accumulation of
myeloblasts in the bone marrow, blood, and other organs [1]. This
complex disease involves multiple genetic and molecular altera-
tions causing cellular transformation, deregulation of apoptosis,
proliferation, invasion, angiogenesis and metastasis [1]. AML pa-
tients typically respond to initial treatment with anthracycline and
cytarabine (1-β-D-Arabinofuranosylcytosine, Ara-C)-based chemo-
therapy, however, the response is poor or short-lived and often
associated with relapse and resistance. The inadequacy of conven-
tionally available therapies in AML has fueled the quest for ﬁnding
new molecules that can be used in chemotherapy with better se-
lectivity and eﬃcacy.
The bis-indole containing alkaloids indigo, indirubin and isoindigo
have been employed in treating myeloid leukemia. The clinical ap-
plication of these drugs in treating myeloid leukemia is hampered
by their potential side effects, poor water solubility, bone marrow
suppression and drug-resistance in prolonged treatments [2]. In ad-
dition, the limited water solubility of these isoindigos hinders the
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detailed characterization of their antiproliferative signaling path-
ways. Thus, extensive efforts have been employed to synthesize novel
indirubin and isoindigo derivatives with increased bioavailability
and bioactivity. In spite of the extensive investigations for the mode
of action of isoindigos in myeloid leukemia and other cancers, there
are gaps in our understanding of their cellular targets and mech-
anism of action.
The antileukemic effects of these compounds are mediated
through multi-signaling pathways including inhibition of DNA bio-
synthesis and assembly of microtubules, arresting cells at G1 phase
of the cell cycle, interactionwith the aryl hydrocarbon receptor (AhR)
triggering cell differentiation and maturation leading to complete
inhibition of cell growth, and down-regulation of c-myb gene ex-
pression [2–6]. Several of these compounds have been shown to
inhibit cyclin-dependent kinases (CDKs) and glycogen-synthase
kinase (GSK-3β), and induce apoptosis with varying degrees of
potency [2–5,7–12]. Recently, a novel 7-azaisoindigo derivative
[namely N(1)-(n-butyl)-7-azaisoindigo] has been shown to trigger
apoptosis through reactive oxygen species (ROS), deregulation of
the mitochondrial functions and activation of caspases [13].
Successful chemotherapeutics are able to trigger death of cancer
cells mainly through intrinsic/extrinsic apoptotic pathways [14].
Apart from extrinsic apoptotic pathway that is dependent on a
receptor-mediated activation of caspase-8, these drugs may stim-
ulate the intrinsic (mitochondria-dependent) pathway which is
evoked by the release of mitochondrial apoptogenic factors such
as cytochrome c to the cytosol allowing activation of caspase-9
[15].
Tumor cells are characterized by having a deregulated cell cycle,
which contributes to their uncontrolled proliferation (reviewed in
Refs. 16 and 17). The molecular mechanisms of cell cycle arrest by
many anticancer agents involve modulation of several cell cycle reg-
ulatory proteins. Although human cells highly express the D type
cyclins (D1, D2 and D3) in early and late G1 phase [18–20], proper
execution of later phases (S and G2-M) require the subsequent ac-
tivation of other CDK-cyclin complexes: CDK2/cyclin E, CDK2/
cyclin A, CDK1/cyclin A and CDK1/cyclin B [16,21]. CDK activity can
be regulated by cell cycle inhibitory proteins (CKI), which bind to
CDK alone or to the CDK/cyclin complex [16,17].
In line with the efforts aiming to synthesize more soluble and
effective anticancer isoindigo derivatives, we have identiﬁed a com-
pound [(E)-1-(5′-bromo-2′-oxoindolin-3′-ylidene)-6-ethyl-2,3,6,9-
tetrahydro-2,9-dioxo-1H-pyrrolo[3,2-f]quinoline-8-carboxylic acid]
(known here as 5′-Br, Fig. 1A) with increased solubility (up to 25mM)
in 25% aqueous DMSO (dimethyl sulphoxide) [22]. 5′-Br effective-
ly inhibited the proliferation of several human hematological and
solid tumor cell lines at low doses in a selective manner [22].
The acute promyelocytic leukemia cell line HL-60 is a subtype
of AML, which accounts for approximately 10% of all AML cases [1].
Therefore, it is an ideal cell line to investigate novel potential che-
motherapeutic agents for this subtype of AML. In this report, we
studied the effect of 5′-Br in triggering apoptosis and cell cycle effects
in HL-60 cells. Evidence suggests that 5′-Br induces mitochondrial
apoptosis in HL-60 cells. 5′-Br triggers depolarization of mitochon-
dria in HL-60 cells, decreases the expression of the anti-apoptotic
protein Bcl-2 and promotes its hyperphosphorylation leading to loss
of functional association with the proapoptotic factor Bax. The
antiproliferative effect is also shown to be through G0/G1 phase
arrest, which is mediated by modulating the expression and func-
tions of the G1 phase-related proteins. 5′-Br inhibited expression
of cyclin D1 and D2, and reduced Rb phosphorylation. It also sig-
niﬁcantly upregulated expression of p21 and inhibited expression
levels as well as activities of CDK2 and CDK4. These results suggest
that the cytotoxic and antiproliferative effects of 5′-Br are medi-
ated by apoptosis, dysregulation of mitochondria functions and cell
cycle checkpoint regulation.
Materials and methods
Reagents
The pyridone-annelated isoindigo 5′-Br compound [[(E)-1-(5′-bromo-2′-
oxoindolin-3′-ylidene)-6-ethyl-2,3,6,9-tetrahydro-2,9-dioxo-1H-pyrrolo[3,2-
f]quinoline-8-carboxylic acid] was previously synthesized and chemically characterized
in details in our recent publication [22]. Other reagents and experimental proto-
cols used in this study are provided in Supplementary Methods.
Cell viability assay
The quantitative determination of viable cells after various treatments was per-
formed by using the dual DNA intercalating ﬂuorescent dyes kit from EMDMillipore
Bioscience (Muse™ Cell Count & Viability Assay). Brieﬂy, 3 × 105 of HL-60, in a 1.0 mL
of RPMI-1640 medium, was seeded in each well of a 24 well-plate. After 24 hr, cells
were exposed to increasing concentrations of 5′-Br (0.0–16.0 μM) for additional 24 hr.
Alternatively, HL-60 cells were incubated with 8.0 μM 5′-Br for different time-
points (0–72 hr) before analysis. Cytarabine (0.01–0.03 μM) was added to HL-60 cells
as positive controls.
Analysis of apoptosis by ﬂow cytometry
The percentage of cells undergoing apoptosis after treatment with 5′-Br was de-
termined using the Muse™ Annexin-V and Dead Cell Assay kit (EMD Millipore
Bioscience) and Muse™ cell analyzer according to the manufacturer’s protocol.
The kit utilizes a ﬂuorescent dye (FITC) conjugated to Annexin-V to detect
phosphatidylserine (PS) on the external membrane of apoptotic cells and 7-AAD (7-
amino-actinomycin D) as a dead cells marker. When z-VAD-FMKwas used, cells were
incubated with the desired concentration of this caspase inhibitor for 4 hr before
addition of 5′-Br. HL-60 cells were also treated with 0.02 μM cytarabine as positive
control.
Analysis of changes in mitochondrial transmembrane potential
Measurement of changes in mitochondria membrane potential (ΔΨm) was per-
formed with the Muse™ MitoPotential Assay kit (EMD Millipore Bioscience). This
ﬂow cytometry-based assay differentiates 4 populations of cells: live cells with de-
polarized mitochondrial membrane; MitoPotential−/7-AAD−, live cells with intact
mitochondrial membrane; MitoPotential+/7-AAD−, dead cells with depolarized mi-
tochondrial membrane; MitoPotential+/7-AAD+ and dead cells with intact
mitochondrial membrane; MitoPotential−/7-AAD+. After treatment with 5′-Br, HL-
60 cells were incubated with the ﬂuorescent dyes and the percentage of depolarized
cells (depolarized alive + depolarized dead) were determined byMuse™ Cell Analyzer.
Quantitation of ATP levels in HL-60 treated Cells
ATP contents were determined using the ATP Colorimetric/Fluorometric Assay
Kit (BioVision, Inc.) according to the manufacturer’s instructions. After treatment
with 8.0 μM 5′-Br for increasing time points, HL-60 (1 × 106) cells were lysed in a
lysis buffer, deproteinized and 10 μL of the supernatant was added to a 50 μL of the
assay reaction mixture. Absorbance was measured at OD 570 nm in a Spectra Max™
micro-plate reader. All samples were measured in triplicates and the values were
expressed relative to the untreated control.
Release of cytochrome c from mitochondria to the cytosol of HL-60 cells
Mitochondrial and cytosolic fractions from HL-60 cells treated with 5′-Br were
prepared by differential centrifugation at 4 °C as described in our recent publica-
tion [23]. The release of cytochrome c from mitochondria into the cytoplasm of 5′-
Br-treated HL-60 cells was detected by Western blotting of mitochondrial (30 μg)
or cytosolic (50 μg) fractions as previously described [23].
Immunoprecipitation and western blot analyses
For immunoprecipitation, 25 × 106 HL-60 were treated with or without 5′-Br for
24 hr. Cells were lysed in ice-cold lysis buffer containing 20 mM Tris–HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 0.5% NP-40, and protease inhibitors [2 μg/mL leupeptin,
2 μg/mL aprotinin, 2 μg/mL pepstatin A and 1 mM PMSF]. After centrifugation at
14,000 g for 20 min at 4 °C, lysates (300 μg) were pre-cleared by incubating (2 hr
at 4 °C) with 25 μL protein A/G plus-agarose beads (Santa Cruz Biotechnology). Pre-
cleared lysates were incubated overnight with 5 μg of speciﬁc anti-Bax or anti-
Bcl-2 antibodies. Immunocomplexes were captured with 25 μL protein A/G plus-
agarose, and the presence of Bcl-2 in these complexes was determined by Western
blot analysis.
Samples preparation and Western blot analysis were performed as previously
described [23]. Primary antibodies against caspase-2 [(C2) Mouse mAb 2224],
caspase-8 [(1C12) Mouse mAb 9746], caspase-9 [(C9) Mouse mAb 9508], cleaved
caspase-3 [(Asp175) (5A1E) Rabbit mAb 9664], cleaved caspase-6 [(Asp162) Anti-
body 9761], phospho-Bcl-2 [antibody 2875] and PARP [antibody 9542] were Obtained
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Fig. 1. The antiproliferative activity of 5′-Br is mediated by apoptosis. (A) Clockwise; the chemical structure of 5′-Br [(E)-1-(5′-bromo-2′-oxoindolin-3′-ylidene)-6-ethyl-
2,3,6,9-tetrahydro-2,9-dioxo-1H-pyrrolo[3,2-f]quinoline-8-carboxylic acid]. Determination of IC50 value: The sigmoidal curve shownwas obtained by plotting themean percentages
of viability versus logarithmic molar concentrations of 5′-Br, and the IC50 value (7.13 μM) was determined using a non-linear regression analysis of GraphPad Prism 6 soft-
ware. Dose dependent decrease in cell viability: HL-60 cells were treated with increasing concentrations of 5′-Br (0.0–16.0 μM), or cytarabine (0.0–0.03 μM) for 24 hr. The
percentage of cell viability was expressed relative to untreated control containing the carrier solvent DMSO. (B) 5′-Br increases apoptosis in a dose dependent manner:
HL-60 cells were treated with varying concentrations of 5′-Br (0.0–12.0 μM) or with 0.02 μM cytarabine for 24 hr and apoptosis was analyzed. The graph represents the
summary mean percentages ± SD of apoptosis (early and late apoptosis) of three independent experiments. Bottom panel shows scatter plots representing percentages of
early and late apoptosis for one experiment. (C) Caspase-3 activity is increased by 5′-Br: Lysates from HL-60 cells, treated with varying concentrations of 5′-Br, were ana-
lyzed for caspase-3 catalytic activity. Caspase 3 activity was completely suppressed by z-VAD-FMK. Increase in cleaved caspase-3 and cleaved PARP levels were observed by
Western blotting. (D) Condensation of chromatin material and fragmentation of nuclei in apoptotic cells: HL-60 cells were treated with 5′-Br or cytarabine for 24 hr and
stained with Hoechst 33342.
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from Cell Signaling Technologies and used in 1:1000 dilution in PBST solution con-
taining 3% bovine serum albumin (BSA). Primary antibodies against Bcl-2 [(C-2): mAb
7382], Bcl-XL [(H-5): mAb 8392], Bax [(N-20): rAb 493] and Bak [(G-23): rAb 832]
(from Santa Cruz Biotechnology) were used in 1:1500 dilution PBST solution con-
taining 5% BSA. Detection of protein of interest was accomplished with secondary
antibodies conjugated to horseradish peroxidase and Pierce ECL Plus substrate so-
lution (Thermo Scientiﬁc, Rockford, Illinois, USA). Pre-stained proteinmolecular weight
markers (Santa Cruz Biotechnology) were included in each gel. To conﬁrm equal
loading of proteins in gels, the blots were also immunoprobedwith an antibody against
α-tubulin [(H-300): rAb 5546] or β-actin [(C4): mAb 47778] from Santa Cruz
Biotechnology.
Flow cytometry analysis of cell cycle
Distribution of cell cycle was analyzed by ﬂow cytometry using the Muse™ Cell
Cycle Kit from EMD Millipore Bioscience. The cell cycle analysis was performed ac-
cording to the manufacturer’s protocol, and as recently described [24]. Brieﬂy,
exponentially growing HL-60 cells (5 × 105 cells/mL) were treated with different con-
centrations of 5′-Br (0.0–12.0 μM) for 24 hr or with 8.0 μM for various periods of
time (0–48 hr). The range of the selected concentrations was based on the demon-
strated IC50 for the compound in HL-60 cells (7.13 ± 0.50 μM). After incubation, 1 × 106
cells were harvested, washed with PBS and ﬁxed with ice-cold 70% ethanol at −20 °C
for 3 hr. The cells were thenwashedwith PBS, stainedwith 200 μL of PI/RNAse reagent
for 30min and analyzed by the Muse™ Cell Analyzer. Adherent cells were trypsinized
after treatment, washed once with PBS, and ﬁxed in 70% ethanol overnight at −20 °C
before analysis as described earlier. All the compound stock solutions were pre-
pared in a solvent containing 50% DMSO and 50% PBS. Therefore, the control cells
were treated with equal amount of the carrier solvent (0.05% DMS0), and showed
no effect on cell cycle when compared with the solvent-free control cells.
CDK2 and CDK4 kinase assay in cell-free systems and in cultured cells
Kinase assays were performed on HL-60 as previously described [25,26], with
some modiﬁcations. For in vitro (cell free system) CDKs kinase assay, exponentially
growing untreated HL-60 cells were lysed for 30 min at 4 °C in the lysis buffer. The
cell lysate was cleared by centrifugation at 14,000 g for 10min at 4 °C. Protein lysates
were pre-cleared twice with 50 μL protein A/G plus-agarose beads. A total of 4 mg
of protein was incubated with anti-CDK2 or anti-CDK4 antibody and protein A/G
plus agarose for 12 hr at 4 °C. The immunoprecipitates were washed three times with
the lysis buffer and twice with a kinase buffer [50mMHEPES (pH 7.0), 10mMMgCl2,
5 mM MnCl2, 1 mM DTT, 5 μM ATP] and separated into 10 tubes. The kinase reac-
tions were done in a ﬁnal volume of 40 μL kinase buffer containing 2 μg histone H1
(for CDK2; Calbiochem, California, USA) or 1 μg Gst-Rb (for CDK4; Santa Cruz Bio-
technology) substrates, various concentrations of the test compound, 20 μM unlabeled
ATP and 5 μCi [γ-32P]ATP (3000 Ci/mmol, PerkinElmer Inc., Waltham, MA, USA), and
carried out for 30 min at 30 °C. SDS sample buffer was then added and the mix-
tures were then boiled for 5 min, and protein was separated on 12% polyacrylamide
gels. The gels were dried, visualized by autoradiography, and the bands were quan-
titated by densitometry.
For in vivo CDKs kinase assay in 5′-Br-treated cell, HL-60 cells (3 × 105/mL) were
seeded in 100 mm plastic culture dishes for 24 hr and subsequently treated with
different concentrations of 5′-Br (0–12.0 μM) for 24 hr or with a ﬁxed concentra-
tion of 8.0 μM for various periods of time (0–48 hr). Cell lysis preparation and
immunoprecipitation were performed as described earlier. Kinase assay was carried
out in 50 μL kinase buffer with CDK2- or CDK4-immunoprecipitates from 300 μg of
protein lysate. Before addition of the radioactive ATP, 10 μL of the slurry was removed
from each sample to separate tubes for Western blot analysis of the immunopre-
cipitated CDK, to verify that equal amount of the desired CDK is present in each
sample. To the remaining 40 μL, 5 μCi [γ-32P]ATP was added to each reaction tube
and the kinase assay was performed as described earlier.
Statistical analysis
Data presented are the means ± SD of results from a minimum of three inde-
pendent experiments with similar patterns unless otherwise mentioned. Statistical
analysis was performed using one-way ANOVA, and Tukey–Kramer multiple-
comparison test was performed by using GraphPad Prism 6 software. A p < 0.05 value
was considered statistically signiﬁcant.
Results
5′-Br inhibits the proliferation of HL-60 cells by apoptosis
5′-Br inhibited the proliferation of HL-60 cells in a dose and time
dependent manner. The cell viability decreased from 89.23 ± 3.24%
at a concentration of 2.0 μM to 22.6 ± 4.23% at 12.0 μM, with an IC50
of 7.13 ± 0.5 μM (Fig. 1A). 5′-Br (8.0 μM) inhibited the growth of HL-
60 cells in a time-dependent manner with >50% loss in cell viability
within 24 hr (Supplementary Fig. S1A). Dose dependent increase in
the percentage of apoptotic cells from 14.24 ± 2.21% to 77.10 ± 3.00%
after treatment with 1.0–12.0 μM of the compound was observed
(Fig. 1B). Induction of apoptosis was time-dependent as shown by
70% increase in apoptotic cells (from 6.50 ± 3.54% to 76.50 ± 9.20%)
after treatment for 72 hr (Supplementary Fig. S1B). The annexin-
V/7-AAD results coincide with the demonstrated effect by viability
assay, and suggest that most of antiproliferative activity of 5′-Br is
mediated by apoptosis. Induction of late apoptotic events were re-
ﬂected by activation of terminal caspase-3 and detection of cleaved
PARP (Fig. 1C), along with condensation of the chromatin material/
fragmentation of nuclei (Fig. 1D) in a dose dependent manner
showing maximum response at 12.0 μM.
5′-Br induced apoptosis could be partially dependent on caspase
activation
In addition to caspase-3, the effect of 5′-Br involved caspases-
2, -8, -9 and -6 as exhibited by increase in their speciﬁc activity and
generation of cleaved products in a dose dependent manner. As
shown in Supplementary Fig. S2A, 5′-Br was found to trigger a dose
dependent increase in the speciﬁc activities of the initiator caspase-
2, -8 and -9, and the effector caspase-6. Processing of initiator
caspase-2, -8 and -9 were demonstrated by the decrease in the levels
of procaspase forms and the appearance of their corresponding
cleaved bands (Supplementary Fig. S2B), while the effector caspase-3
and -6 by the increase in the level of the small subunits of the active
enzymes (Fig. 1C and Supplementary Fig. S2B).
To further validate 5′-Br-induced caspase dependent apoptosis
in HL-60 cells, we analyzed the cell death triggered by the com-
pound in the presence of the general caspase inhibitor z-VAD-
FMK (Fig. 2). While the presence of 40.0 μM of z-VAD-FMK was
adequate to completely inhibit the 5′-Br-induced activation of all
the tested caspases (Fig. 1C and Supplementary Fig. S2A), it caused
only ~31% cells to be relieved of apoptosis (Fig. 2). These results in-
dicate that the 5′-Br-induced apoptosis could be, at least in part,
dependent on caspase activation.
Role of mitochondria in 5′-Br-induced apoptosis in HL60 cells
In response to 5′-Br treatment, HL-60 cells were found to dem-
onstrate a dose and time dependent increase in the mitochondrial
depolarization, reﬂected by increase in percentage of depolarized
cells (depolarized-live + depolarized-dead cells). An increase in de-
polarization from 9.57 ± 5.31% in the untreated control cells to
54.07 ± 2.10% and 66.21 ± 7.64% in the presence of 8.0 μM and
12.0 μM of 5′-Br was observed, respectively (Fig. 3A). Cells treated
with 40.0 μM of z-VAD-FMK prior to addition of 8.0 μM of the com-
pound resulted in only ~27% recovery of depolarization, suggesting
that 5′-Br-induced disruption of mitochondria transmembrane po-
tential is mostly caspase-independent. 5′-Br induced a time-
dependent increase in the percentages of depolarized cells. A
signiﬁcant change in the mitochondria membrane potential was
evident after incubation with 8.0 μM of the compound for 8 hr
(25.00 ± 5.09%) and reached the peak value (55.50 ± 5.94%) after 20 hr
(Fig. 3B). These results indicate that 5′-Br induces change in mito-
chondrial membrane potential in both dose and time dependent
manner. 5′-Br-induced disruption of mitochondrial transmem-
brane potential interferes with ATP synthesis as shown by time
dependent decrease in the relative levels of cellular ATP (Fig. 3C).
The mean relative level of ATP decreased to 58.30 ± 6.7% after 24 hr.
Further, cytosolic cytochrome c was increased proportionally to
5′-Br concentration (Fig. 3D). The levels of cytochrome c that re-
mained in the mitochondria of treated HL-60 cells decreased
concomitantly (Fig. 3D). Detectable increase in the cytosolic cyto-
chrome c was seen as early as 12 hr after incubating HL-60 with
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8.0 μM of 5′-Br (Supplementary Fig. S3A). However, the leakage of
cytochrome c to the cytosol was not signiﬁcantly inhibited by z-VAD-
FMK, suggesting that its triggered release from mitochondria is
independent of activation of caspase (Supplementary Fig. S3B). The
release of cytochrome c coincides with the demonstrated 5′-Br dose
and time dependency disturbance of mitochondrial functions and
induction of apoptosis.
Expression and function of Bcl-2 protein are modulated by 5′-Br
Exposure of HL-60 cells to 5′-Br decreased the expression levels
of the antiapoptotic protein Bcl-2 in a dose dependent manner
(Fig. 4A and 4B). But there was an increase in phosphorylated forms
of Bcl-2. However, the amount of the proapoptotic proteins Bax and
Bak remains unchanged under the same treatment conditions. Also,
the antiapoptotic Bcl-XL protein levels did not change in the pres-
ence of 5′-Br (Fig. 4A).
Semi-quantitative RT-PCR results indicate that decreased level
of Bcl-2 protein is due to the effect on gene expression rather than
its post-translational degradation. Relative expression level of Bcl-2
was suppressed by a magnitude of ~6-fold in cells treated with
8.0 μM 5′-Br (Fig. 4C).
To monitor the effect of 5′-Br-induced hyperphosphorylation of
Bcl-2 on its association with Bax, the Bax complex was immuno-
precipitated from treated cells at different doses and the level of
co-immunoprecipitated Bcl-2 in each complex was determined. As
shown in Fig. 4D, the level of Bcl-2 co-immunoprecipitated with Bax
from treated cells was signiﬁcantly lower. The reciprocal immuno-
precipitation experiment, under similar treatment conditions using
an anti-Bcl-2 antibody, also showed a substantial concentration de-
pendent reduction in the level of the co-immunoprecipitated Bax
in treated cells (Fig. 4D). The association between Bcl-2 and Bax was
dependent on the dose of 5′-Br and coincided with dose depen-
dent hyperphosphorylation of Bcl-2 (Fig. 4A).
5′-Br induces cell cycle arrest in the G0/G1 phase by modulating the
expression of regulatory proteins
When cells were treated with increasing concentrations of 5′-
Br for 24 hr, a dose dependent cell cycle arrest at G0/G1 phase was
evident with concomitant decrease in the S and G2/M phases. After
treatment with 12.0 μM 5′-Br, cell population in G0/G1 phase in-
creased by ~60%, whereas cells in G2/M and S phase were decreased
by ~77% and ~36 % respectively (Fig. 5A). The cell cycle arrest was
time dependent as exhibited by maximum response observed at
48 hr with ~54% increase in G0/G1 cell population (Supplementary
Fig. S4). Change in cell population at different stages was accom-
panied by the change in the level of associated regulatory proteins.
Cyclins D1 and D2 were found decreased along with cyclin depen-
dent kinases, CDK2 and CDK4 but cyclin D3, cyclin E and CDK6 were
not signiﬁcantly affected by 5′-Br treatment (Fig. 5B). The expres-
sion of total Rb protein remained almost unchanged, while the
phosphorylated-Rb signiﬁcantly decreased in a dose dependent
fashion (Fig. 5C). Expression of CDK inhibitors was found modu-
lated as exhibited by increase in p21 levels (Fig. 5D).
Cyclin dependent kinase activity is inhibited by 5′-Br
In cell-free system, CDK2 and CDK4 were immunoprecipitated,
and their activity wasmeasured using histone H1 (for CDK2) or GST–
Rb fusion protein (for CDK4) as substrates in the presence of [γ-
32P] ATP. In vitro, 5′-Br was able to inhibit both CDK2 (Fig. 6A) and
CDK4 (Fig. 6B) with an approximate IC50 of ~6.48 ± 0.32 μM and
~4.85 ± 0.45 μM, respectively. The kinase activities of both CDK2
and CDK4 were inhibited in a dose dependent manner, and >95%
of the substrates phosphorylationwas observed after incubationwith
Fig. 2. Apoptosis induced by 5′-Br in HL-60 cells is partially dependent on caspase
activation. z-VAD-FMKwas able to partially rescue (31%) apoptotic cells. Bottom panel
shows scatter plots representing one ﬂow cytometry experiment. The graph rep-
resents the summary mean percentages ± SD of apoptosis (early and late apoptosis)
of three independent experiments. (**) For values that are signiﬁcantly different from
untreated control (p < 0.05).
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12.0 μM of 5′-Br (Fig. 6C and 6D). The inhibitory activity of 5′-Br was
found to be time dependent with complete inhibition observed at
48 hr (Supplementary Fig. S5A and S5B).
Discussion
In the present study, we aim to analyze possiblemodes of action
of a novel isoindigo compound (5 ′-Br) in human promyelocytic leu-
kemia cells. We provide evidence that suggests involvement of
apoptosis, mitochondrial dysfunction and cell cycle regulation as
potential mechanisms. The antitumor properties of isoindigo de-
rivatives have been studied with respect to apoptosis and cell cycle
arrest (reviewed inRef. 27). Indirubins and isoindigos appear to induce
different cell deathmechanism(s) that is determined by their struc-
tures. For 5′-Br-induced cell death, apoptosis seems to be the primary
mechanism. This is supported by the following ﬁndings: ﬁrst, 5′-
Br-treatedHL-60 cells showed themorphological aspects associated
with early and late apoptotic events. Second, 5′-Br induced activa-
tion of the initiator caspases (-2, -8, and -9) and terminal caspases
(-3 and -6). Third, 5′-Br caused cleavage of PARP, condensation of
Fig. 3. 5′-Br induces dysfunctioning of mitochondria in HL-60 cells that is mostly independent from activation of caspases. (A) HL-60 cells were treated with varying con-
centrations of 5′-Br (0.0–12.0 μM) or 0.02 μM cytarabine in the presence and absence of 40 μM z-VAD-FMK for 12 hr. The scatter plots showing the percentages of live and
dead depolarized cells are indicated for one experiment. The bar graph represents the mean percentages ± SD of total number of depolarized cells. (B) Peak depolarization
effect of 5′-Br was observed at 20 hr treatment: HL-60 cells were exposed to 8.0 μM 5′-Br for increasing intervals and depolarization was assessed as described. (C) 5′-Br
causes decrease in ATP levels: HL-60 cells were exposed to 8.0 μM 5′-Br for increasing periods and the level of ATP, relative to the untreated control, was determined as
described. All the data shown represent the mean ± SD of three independent experiments. (**) For values that are signiﬁcantly different from the proper control. (D) 5′-Br
causes releases of cytochrome C in the cytosol: Immunoblot studies show mitochondrial (Mit., 30 μg fraction) cytochrome c levels decreased and cytosolic (Cyt., 50 μg frac-
tion) levels increased in response to 5-Br treatment.
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chromatin material and fragmentation of nuclei in apoptotic HL-
60 cells. Finally, 5′-Br caused depolarization of mitochondria (loss
of ΔΨm) and caused the release of cytochrome c into the cytoplasm
in a dose and time dependent manner, a characteristic for numer-
ous stimuli that cause apoptosis via the intrinsic pathway involving
mitochondria [14,28]. These evidence suggest involvement of
apoptotic pathway in the mode of action of 5′-Br. Similar to HL-60
cells, 5′-Br induced apoptosis and activation of caspase-3 in K562,
THP-1, HepG2, MCF-7, Caco-2 cell lines (Supplementary Fig. S6).
We further analyzed the depolarization of cells in response to
5′-Br to establish the involvement of mitochondrial dysfunction. In-
volvement of mitochondrial dysfunction was evident by the increase
in number of depolarized cells in a dose and time dependentmanner.
However, our ﬁndings that z-VAD-FMK only partially rescued 5′-
Br-treated cells from apoptosis and change in the mitochondria
transmembrane potential (ΔΨm) suggest the involvement of caspase-
dependent and caspase-independent pathways of cell death.
Interestingly, the presence of z-VAD-FMK also did not inhibit ATP
depletion (Supplementary Fig. S7), suggesting that the 5′-Br-
induced dysfunctioning of the mitochondria in HL-60 cells is
independent of caspase activation.
Since the activity of the Bcl-2 family proteins can be affected in
cancer cells ormodulatedupon exposure to chemotherapeutic drugs,
we have investigated the contribution of the major players in this
family. We found that 5′-Br treatment resulted in a substantial de-
crease in expression of Bcl-2, while the levels of Bax, Bak and Bcl-
xL were not affected. An increase in the ratio of Bax/Bcl-2 or Bak/
Bcl-xL stimulates the proapoptotic proteins Bax and Bak to form
channels in the outer mitochondria membrane allowing cyto-
chrome c to escape into the cytosol. The cytosolic cytochrome cwill
Fig. 4. 5′-Br modulates the expression and phosphorylation of Bcl-2, and its association with Bax. (A) 50 μg protein lysates, from HL-60 cells treated with increasing con-
centrations of 5′-Br, were immunoblotted with antibodies against Bcl-2, phospho-Bcl-2, Bcl-XL, Bax, Bak and α-tubulin. Cont: DMSO treated control. (B) Densitometric scanning
for the intensity levels of Bcl-2 (relative to untreated control), obtained fromWestern blotting of the protein in HL-60 cells treated with different concentrations of 5′-Br for
24 hr show decrease in levels of BCl-2 protein. The values represent the mean relative band densities ± SD of two independent experiments. (C) Semi-quantitative RT-PCR
for Bcl-2 mRNA obtained from untreated or treated cells with 5′-Br for 24 hr show a decrease in Bcl-2 mRNA levels. The densities of visualized bands (from three indepen-
dent trials) were quantitated and the values were normalized to β-actin intensity levels. (**) For values that are signiﬁcantly different from untreated control. (D) Bax or
Bcl-2 were immunoprecipitated from whole cell lysates (300 μg), obtained from untreated and treated HL-60 with 5′-Br, and the presence of Bcl-2 or Bax in these com-
plexes (IP) was visualized by Western blot analysis. The heavy chain of Bax and Bcl-2 antibodies (Ab-Hc) are also shown. Immunoblotting (IB) for Bcl-2, Box and phosho-
Bcl-2 from 50 μg protein of the whole cell extracts (WCE) are shown to validate that the reduced amounts of coimmunoprecipitated Bcl-2 or Bax are due to loss of their
protein–protein interactions, rather than variations in the protein levels.
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bind and activate Apaf-1-caspase-9 apoptosome, leading to acti-
vation of caspase-3 [28]. Our data support this mechanism as
evidenced by release of cytochrome c in the cytosol. These results
may be responsible for the concomitant execution of apoptosis that
we observed.
Our results show that 5′-Br is able to inactivate Bcl-2 via ex-
pression and hyperphosphorylation control. Activated caspases can
cleave Bcl-2, generating an inactive form of the protein [29]. In ad-
dition, down-regulation of Bcl-2 mRNA or Bcl-2 protein have been
observed after treatment with different anticancer drugs [30,31].
In 5′-Br-induced apoptosis, the total Bcl-2 levels are decreased, sug-
gesting that caspase-dependent cleavage, ubiquitin-directed
degradation of the protein or alterations of mRNA levels maybe be
involved. Although the 5′-Br-dependent cleavage or degradation of
Bcl-2 cannot be ruled out, we could not detect the presence of short
form (23 kD) of protein in western blots or ubiquitinated form in
Bcl-2 immunoprecipitates from5′-Br treated cells (data not shown).
The levels of Bcl-2mRNAweredecreased in adosedependentmanner,
suggesting that 5′-Br interfereswithBcl-2 gene expression. The tumor
suppressor protein p53 was reported to regulate Bcl-2 family pro-
teins through transcription-dependentand-independentmechanisms
[32]. However, 5′-Br-induced alteration of Bcl-2 expression in HL-
60 cells seems tobe independent of p53, since these cells are deﬁcient
in functional p53 [33,34]. Phosphorylation of Bcl-2 has been dem-
onstrated as amechanism formodulating the activity of the protein
[35]. Our results show that 5′-Br induces a dose dependent in-
crease in Bcl-2 hyperphosphorylation that correlates with loss of
its heterodimerizationwith Bax in the immunoprecipitated complex
from HL-60 treated cells. These results are consistent with several
previous reports showinghyperphosphorylationof Bcl-2was induced
by cytotoxic drugs and chemotherapeutics, e.g. Vinca alkaloids,
paclitaxel, doxorubicin and etoposide [36–38].
Our results support that 5′-Br triggers the intrinsic mitochon-
drial pathway of apoptosis. However, we cannot rule out the potential
involvement of extrinsic receptor pathway(s) of apoptosis in 5′-Br
treated cells. The later possibility is supported by 5′-Br induced ac-
tivation of caspase-8. However, whether activation of caspase-8 is
involved in 5′-Br-induced apoptosis or consequent to activation of
Fig. 5. 5′-Br induces a cell cycle arrest at G0/G1 phase in HL-60 cells. (A) In response to 5′-Br treatment an increase in the cell population at G1/G0 phase is observed rep-
resented by blue peak. Bottom panel shows bar graph representing quantiﬁed values of the ﬂow cytometry data. Data shown are representative of one experiment. The
graphs show the mean ± SD of the three independent cell cycle experiments. (**) For values that are signiﬁcantly different from the untreated control. (B) HL60 cells were
treated with increased concentrations of 5′-Br (2.0–12.0 μM) for 24 hr, then 50 μg of whole cell lysate was analyzed by Western blotting with antibodies against cyclins
(D1, D2, D3 and E) and CDKs (CDK2, 4 and 6), (C) Rb and phospho-Rb, (D) and p21 and p27. The immunoblots shown are representations of two independent experiments.
The same membranes were also probed with an antibody against α-tubulin as loading controls. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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effector caspase-3 triggered by the release of cytochrome c remains
to be investigated. Similarly, it is yet unclear whether 5′-Br-
induced activation of the initiator caspase-2 is due to sequential
activation of other caspases or response to potential direct action
of the compound on damaging the DNA of HL-60 cells [39].
Several compounds similar to 5′-Br have been shown to arrest
cell cycle, leading to cell death, by inhibiting CDKs and GSK-3βwith
varyingdegrees of potency [2–5,7–12,40].We thus analyzed the effect
of 5′-Br on cell cycle checkpoint regulation. Indirubin and several
of its analogs exhibit their anticancer activity through modulating
CDKs, which arrest cell cycle progression leading to apoptotic cell
death [2–5,7–12,40]. Leclerc and coworkers have shown that the
antiproliferative effect of indirubins is related to their ability to inhibit
the kinase activity of GSK-3β, CDK1/cyclin B andCDK5/p25 [9].Moon
and coworkers [5] have synthesized novel indirubin analogs and
shown that the antitumor activities aremediated by their ability to
bind and inhibit the catalytic subunit of CDK2.Natura™,meisoindigo
and other related compounds have been demonstrated to induce
apoptosis in various cancer cell lines and inhibit the activity of CDK4,
leading to cell cycle arrest at the G0/G1 phase [41]. Here we show
that 5′-Br inhibits cell cycle progression and induces cell-cycle arrest
in the G0/G1 phase in HL-60 cells both in a dose and time depen-
dent manner. D-type cyclins (D1 and D2), CDK2 and CDK4 were
signiﬁcantly down-regulated leading to cell cycle arrest at G0/G1.
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Fig. 6. 5′-Br inhibits the kinase activities of CDK2 and CDK4 in cell-free system and cultured HL-60 cells. CDK2 (A) and CDK4 (B) immunoprecipitated complexes were pre-
pared from exponentially growing untreated cells, and reacted with [γ-32P]ATP in the presence of histone H1 (for CDK2, A) and GST-Rb (for CDK4, B) substrates and increasing
concentrations of 5′-Br as described under the methods. Quantiﬁcation of the histone H1 and GST-Rb-phosphorylated forms was performed by densitometric analysis, and
the IC50 was calculated using a non-linear regression analysis of GraphPad Prism 6. Data represent the means ± SD of three independent experiments. (**) For values that
are signiﬁcantly different from untreated control. (C and D) HL-60 cells were treated with various concentrations of 5′-Br (0.0–12.0 μM) for 24 hr. Total cell lysates were
used for immunoprecipitation, and the kinase activities were assayed with histone H1 (C, for CDK2) and GST-Rb (D, for CDK4) as substrates. Data shown are representative
of two independent experiments. The graphs represent themean of the densitometric intensities of the visualized bands. The same immunoprecipitates were also immunoblotted
with CDK2 and CDK4 to verify equal amounts of the desired CDK were present in each sample.
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The CDK2 and CDK4 inhibition due to direct and indirect actions
of 5′-Br could lead to hypophosphorylation of Rb in the treated cells.
Though, the expression level of Rb is not affected, phosphorylated
Rb levels decreased signiﬁcantly in a dose dependent manner, in-
dicating that 5′-Br can suppress the phosphorylation of this protein.
Similar mechanism of inhibiting cell cycle progression to prevent
cell proliferation has been reported earlier [20,42,43].
Our results show that 5′-Br induces a dose dependent increase
in p21 which might lead to a reduction in the phosphorylation of
Rb leading to cell cycle arrest at G0/G1 [44]. The expression of p21
gene is controlled by p53-dependent and p53-independent mecha-
nisms [45–47]. However, HL-60 and several other cancer cell lines
are deﬁcient in functional p53 [33,48,49], suggesting that 5′-Br-
induced up-regulation of p21 is controlled via p53-independent
mechanism.
The kinase activity of CDK2 and CDK4was found inhibited in vivo
in a dose and time-dependent manner in HL-60 treated cells.
However, it is possible that 5′-Br inhibits the CDK activating kinases
(CAKs) or activates the CDK-inactivating phosphatases, which are
regulators for CDK function. Therefore, additional studies are needed
to determine whether the inhibition of CAKs or activation of CDK-
inactivating phosphatases contributes to the inhibition of the kinase
activity of CDK2 and CDK4. In addition, CDK6 can also phosphory-
late Rb within cells. The question of whether or not 5 ′-Br directly
inhibits CDK6 activity remains to be answered. Furthermore, al-
though down-regulation of D-type cyclins by 5′-Br suggests that it
is the main causal effect for inhibiting the CDK4 kinase activity, we
cannot rule out the possibility that the test compound may block
cyclin D binding to CDK4, or binding of other cyclins to their spe-
ciﬁc CDKs, thereby inhibiting CDK4/cyclin D complex activity. Our
results thus establish that 5′-Br arrests cell cycle at G0/G1 through
its direct binding to the catalytic subunit of CDK2 and CDK4 and
indirectly by modulating the expression of the two CDKs, cyclin D
and p21.
The compound also inhibits G0/G1 cell cycle progression in K562,
THP-1, HepG2 and MCF-7 (Supplementary Table S1). 5′-Br shows
a dose-dependent accumulation of G2/M population in Caco-2 cells.
This suggests that the targeted CDK/cyclin complexes by the com-
pound may vary in different cancer cell lines (Supplementary Table
S1). Caco-2 cells are heterogeneous, microsatellite stable [50] and
have been reported to employ G2/M checkpoint regulation with in-
creased p21 expression in response to dietary isothiocyanates [51].
Further mechanistic studies will provide insights into effect of 5′-
Br in Caco-2 cells.
The potent inhibitory effects of 5′-Br against CDK2 and CDK4
prompted us to dock this compound into the binding pockets of both
proteins and compare its optimal docked poses with the co-
crystallized poses of corresponding potent ligands. Supplementary
Fig. S8 compares how the potent CDK2 inhibitor, staurosporine, binds
within CDK2 kinase binding pocket (PDB code: 4ERW, resolution
2.0 Å) with the way 5′-Br docks into the binding pocket of the same
protein. Supplementary Fig. S8C and S8D suggests the 2-pyrrolidone
of staurosporine and the 2-indolone of 5 ′-Br share similar hydro-
gen bonding pattern with the peptidic NH of Leu83 and the peptidic
carbonyl of Glu81. Supplementary Fig. S9 compares how a potent
CDK4 inhibitor (PDB code: 1PU501) binds within the X-ray crystal
structure of CDK4 mimic CDK2 (PDB code: 1GIH, resolution 2.80 Å)
with theway 5′-Br docks into the binding pocket of the same protein.
Incidentally, inactive CDK2monomer is closely homologous to CDK4
and therefore was used as a structural surrogate for CDK4 [52]. These
docking studies suggest that 5′-Br may directly bind to the ATP
binding site of the catalytic subunit of CDK2 and CDK4.
In conclusion, we have demonstrated that the antiproliferative
activities of 5′-Br in HL-60 cells are primarily mediated by apoptosis,
dysregulation of mitochondrial functions and arresting cell cycle
at G0/G1 phase. These data, in addition to the previous ﬁnding
that 5′-Br has a higher water solubility than the other reported
isoindigos, and its ability to selectively induce apoptosis and cell
cycle arrest in various cancer cell lines, but not in noncancerous
cells at low exposure doses, strongly nominate this compound as
a chemotherapeutic candidate. Therefore, detailed elucidation of
the pathways and the respective targets of 5′-Br involved in apop-
tosis and cell cycle are critical for its potential application in cancer
therapy. This study provides comprehensive analysis that paves the
way for characterization of this novel molecule with potential an-
ticancer effect.
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